Viking Therapeutics, Inc. (VKTX)
Chart Events
Performance Outlook
| Previous Close | 5.91 |
| Open | 6.12 |
| Bid | 5.94 x 2900 |
| Ask | 5.96 x 2200 |
| Day's Range | 5.92 - 6.12 |
| 52 Week Range | 4.55 - 10.09 |
| Volume | 752,052 |
| Avg. Volume | 1,458,586 |
| Market Cap | 438.868M |
| Beta (5Y Monthly) | 1.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.54 |
| Earnings Date | Feb 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.71 |
- Insider Monkey
Bumbershoot Holdings: “Viking Therapeutics (VKTX) Struggled Right Off the Bat”
Bumbershoot Holdings LP, an investment management firm, published its fourth quarter 2020 investor letter – a copy of which can be downloaded here. Bumbershoot Holdings L.P. generated a negative gross return of -6.61% for the full-year 2020, while its S&P 500 benchmark delivered a 16.26% return in the same period. You can view the fund’s […]
- PR Newswire
Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the 20th Annual Needham Virtual Healthcare Conference. The conference, which will take place April 12-15, 2021, is being conducted with a virtual format.
- PR Newswire
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in three upcoming investor conferences.
